Mymetics Virosomes Successful in Allergy Proof-of-Concept Study
Epalinges, Switzerland, December 13, 2018 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that the pre-clinical proof-of-concept study for allergies, with their partner Anergis SA, has met the success criteria.
| Media Name | Media Type | Description | Download |
|---|---|---|---|
| press release pdf | Download |